Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4272 - CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC


11 Sep 2017


Poster display session


Michelino De Laurentiis


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


M. De Laurentiis1, M. Martin Jimenez2, A. Ring3, P. Cottu4, K. Zhou5, J. Wu5, J.P. Zarate5, C. Zamagni6

Author affiliations

  • 1 Breast Oncology, IRCCS Fondazione G. Pascale, 80131 - Naples/IT
  • 2 Medical Oncology Service, Universidad Complutense de Madrid and Hospital General Universitario Gregorio Marañón, Madrid/ES
  • 3 Department Of Medicine  , Royal Marsden Hospital NHS Foundation Trust  , SW3 6JJ - London and Surrey/GB
  • 4 Medical Oncology, Institut Curie, Paris/FR
  • 5 Oncology Global Medical Affairs, Novartis Pharmaceuticals, East Hanover/US
  • 6 Addarii Medical Oncology Unit, Orsola-Malpighi Hospital, Bologna/IT


Abstract 4272


CDK4/6 inhibitor ribociclib was recently approved in the United States in combination with letrozole for the treatment of HR+, HER2– ABC in postmenopausal women with no prior therapy for advanced disease, based on the significantly prolonged PFS versus placebo plus letrozole observed in the pivotal phase 3 MONALEESA-2 trial (Hortobagyi et al. NEJM 2016). The phase 3b CompLEEment-1 study will further evaluate the safety and efficacy of ribociclib plus letrozole as first-line therapy in an expanded patient population.

Trial design

In this open-label study, men or women of any menopausal status with HR+, HER2– ABC will receive ribociclib (600 mg/day, 3 weeks on/1 week off) + letrozole (2.5 mg/day); men and premenopausal women will receive concomitant goserelin (3.6 mg subcutaneous implant every 28 days). Treatment will continue until disease progression or unacceptable toxicity. Patients are limited to ≤ 1 line of chemotherapy and no prior ET for advanced disease; patients receiving (neo)adjuvant ET with a nonsteroidal aromatase inhibitor must have a disease-free interval of > 12 months. Exclusion criteria include Eastern Cooperative Oncology Group performance status >2, or prior CDK4/6 inhibitor treatment. Planned hematologic and chemistry laboratory assessments will be completed every 2 weeks for the first 2 months, then monthly to Cycle 6, and as clinically indicated to Cycle 36. Tumor assessments are recommended every 12 weeks or at intervals per local standard of care during the treatment phase. The primary outcome is safety and tolerability. Secondary outcomes include time to progression, clinical benefit rate, overall response rate, safety, and patient-reported outcomes (PROs). Adverse events and drug-drug interactions will be monitored using CT Scholar; PROs will be collected for female patients using the FACT-B questionnaire to better understand health-related quality of life and treatment side effects. Global recruitment of the planned ∼3,000 patients is ongoing, with the majority occurring in Europe.

Clinical trial identification


Legal entity responsible for the study

Novartis Pharmaceuticals


Novartis Pharmaceuticals


M. De Laurentiis: Provided consulting or advisory role and participated in a speakers\' bureau for Novartis, Roche, Pfizer, AstraZeneca, Celgene and Eisai. M. Martin Jimenez: Consulting or Advisory role from Roche/Genetech, Novartis, Amgen, Pfizer, Lilly. The institution received funding from Novartis. A. Ring: Consulting or advisory role for Novartis, Roche, and Genomic Health. P. Cottu: Consulting or advisory role and received honoraria from Pfizer, AstraZeneca, Novartis and Roche. Conducted research project funded by Novartis, Pfizer and Genotech. K. Zhou, J. Wu, J.P. Zarate: Employee of Novartis Pharmaceuticals Corporation. C. Zamagni: Consulting, advisory role, travel, accomodations, expense and/or research funding from Roche, Genomic Health, Pierre Fabre, Eisai, Novartis, AstraZeneca, Celgene, Medivation, Abbvie, Pfizer, Array BioPharma, Morphotek.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.